September 27, 2016 5:13pm

… Equities trip at mid-day to regain position

A note of caution; volume is increasing …

 

Pre-open indication’s tally:  4 hits <AGTC, BLCM, BSTG, JUNO and KITE > and 1 miss <CLLS>

 

I answer one question; in which company should investors put, keep and commit their money!

 

Do you care what happened today, you should because it has implications to Wednesday's sector activity?  

Subscribe or lose!

 

I say what others won't, so you can do what others can't!

 

 

There are two things that investors need - interpretation of news and translation of market metrics concerning the stem, cell, gene and regenerative therapy sector to substantiate share pricing.

 

 

The market received a boost from a number of economic data releases. There's a premium on data at this time because the data recently has been slipping.

The NASDAQ closed UP +48.22 or +0.92% to 5,305.71 and the DOW closed UP +133.47 or +0.74% to 18,228.30.

 

 

A day in the life of the stem, cell, gene and regenerative therapy (SCGT & RT) sector – the advance/decline line scenario of our 43 covered companies:   

  • The open was positive with an A/DL of 27/14 and 2 flats;
  • The mid-day slipped negative with an A/DL of 20/22 and 1 flat;
  • The closing bell  jumped positive with A/DL of 27/15 and 1 flat;

 

 

Henry’omics:

The stem, cell, gene and regenerative therapy (SCGT&RT) sector was positive at the opening bell, slipping negative at the mid-day with the sector closing positive.

I keep telling investors in the a.m. to check the indexes:  

  • The iShares Russell 2000 (IWM) indicated a positive +0.16% and was UP +0.41% at the close while the iShares Nasdaq Biotechnology (IBB) was indicated a positive +0.09% this a.m. and closed UP +1% at the close.
  • The IWM and IBB tell a story about today and tomorrow.

Unfortunately, the stem, cell, gene and regenerative therapy sector (SCG&RT) is swinging wildly between volume and volatility.

  • Which reminds me of hearing Paul Simon in the background: “Slip slidin’ away, slip slidin’ away, you know the nearer your destination the more you’re slip slidin’ away.”

The focal point of this market is that that Q3 is about to end; in my opinion, financial results/earnings are all about expectation.

  • Where past earnings expectations were low, expectations for this coming quarter are basically stagnant – basically loss-per-share (LPS) metrics will be incrementally up, and they are even more ominous for Q4.

 

Call me cantankerous, contrarian or even a curmudgeon but at the least I get it right and investors make money!

 

 

Pre-open indications: 5 hits and 1 miss:

  • Juno Therapeutics (JUNO) closed UP +$3.77 – hit;
  • Cellectis SA (CLLS) closed DOWN -$0.20 – miss;
  • Biostage (BSTG) closed DOWN -$0.02 – hit;
  • Bellicum Pharma (BLCM) closed UP +$1.40 – hit;
  • Applied Genetic Technologies (AGTC) closed UP +$0.30 – hit;
  • Kite Pharma (KITE) closed UP +$5.06 – hit;

 

 

Today’s Bottom Line:

The sector and the market was influenced by last night’s debate, it was on everyone’s tongue. Who won last night?  I don't think either candidate represented the voting public!

  • Irrespective of who won the first debate, it is important to remember there are two more debates ahead.

 

 

Review my fear gauge or the CBOE Volatility Index (VIX):

  • Tuesday traded near 13.2;
  • Monday traded near 14.3 -16.5% higher;
  • Friday traded near 12.2 – I still don’t see it in our universe;
  • Thursday traded 11.3, -16.46% lower – I don’t see it in the SCG&RT sector;
  • Wednesday traded near 13.9, -2.6% lower;
  • Last Tuesday traded 15.9;

 

 

Decliners:

  • Fate therapeutics (FATE) -4.40%;
  • BioTime (NYSEMKT: BTX) -3.53% post Monday’s +4.47% after Friday’s +5.57% after Thursdays +3.16%;
  • Mesoblast (MESO) -3.17%;
  • International Stem Cell (ISCO) -2.17%;
  • ImmunoCellular (NYSEMKT: IMUC) -1.35%

 

Advancers:

  • Juno Therapeutics (JUNO) +12.72%;
  • Kite Pharma (KITE) +9.20% post Monday’s +0.75%;
  • Bellicum Pharma (BLCM) +7.24%;
  • Stemline (STML) +5.05% post Monday’s +1.13%;
  • Adverum (ADVM) +4.73%

 

Flat:                                                                                                              

  • ReNeuron (RENE.L) at $2.625;

                                                                                                                               

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.